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Interest of the SYNTAX Score to predict cardiovascular outcomes
after stenting of unprotected left main coronary artery stenosis :
2 Years Follow-up of the ALMA registry
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Aims: The SYNTAX (SX) score, an interesting tool to characterize the
severity of the coronary artery disease was designed to predict cardiovascular
outcomes in patients with three-vessel or unprotected left main coronary artery
(ULMCA) disease in the SYNTAX study. However, the prognostic value of
SX score in patients undergoing percutaneous coronary intervention (PCI) of
ULMCA stenosis needs to be validated in the “real world”. The aim of our
study was to evaluate the clinical outcome of all the patients undergoing PCI
for ULMCA stenosis according to the SX score in a monocentric registry. 
Methods and results: Forty-five patients with de novo ULMCA stenosis
(mean age 72±10 years; 76% of male) underwent PCI with bare metal stent
(BMS) or drug eluting stent (DES) from January 2006 to December 2008 and
were included in the ALMA (Angioplasty of Left Main at lAriboisière hos-
pital) registry. Twenty nine percent of patients were diabetics, mean ejection
fraction (EF) was 54±10%. EuroSCORE value was 5.4±3.2 and SX score was
22±8. Ostial ULMCA stenosis was involved in 27% and distal ULMCA lesion
in 62% of cases. Distal ULMCA stenoses were treated by provisional T
stenting in most of the cases, with one stent implantation in 48% of patients
and with two stents in 44%. Clinical follow-up was achieved in all patients
(25±10 months). In-hospital MACCE occurred in 6.7% of patients (2 death
and 1 myocardial infarction). The rate of major adverse cardiac or cerebrovas-
cular events (MACCE) was 35.6%. Cardiac mortality in the registry was 8.8%
at two years. Target lesion revascularisation occurred in 15.6% of patients
(7.1% in the DES group vs. 19.4% in the BMS group; p=0.31). None of the
patients showing restenosis died. SX score was correlated to MACCE and car-
diovascular death. A higher SX score (≥33) compared to the lower group (SX
score between 0 to 32) is significantly associated with MACCE (83,3% vs.
28,1%; p<0.01) and cardiac mortality (33.3% vs. 7.7%; p=0.04).
Conclusions: The SX score is a useful tool to predict MACCE and cardiac
mortality in patients undergoing percutaneous revascularization of the left
main coronary artery.
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The large reduction in restenosis rates with drug-eluting stents (DES), com-
pared with bare-metal stents (BMS), has already been demonstrated. In those
studies this gain was not associated with safety concerns such as excess early
and late stent thrombosis (ST). 
We tried to determine predictive factors of drug eluting instent thrombosis in
a tertiary center.
Our study is retrospective enrolling 619 patients who underwent drug
eluting stenting. Thrombosis definition was based on the Academic Research
Consortium (ACR 2008), We compared 2 groups T+ (thrombosis) et T- (no
thrombosis).
The rate of thrombosis was 3,7% (23 patients among 619). This complica-
tion occurred at a mean follow-up of 21,43 days. There were one case of acute
thrombosis, 21 cases of subacute Thrombosis, one case of late thrombosis. No
very late thrombosis was noted. Patients who had thrombosis were older (T+=
67years old; T-=63,16 years old), more diabetic (T+=65% ; T-=61,5%) but
without significant difference . The occurring of stent thrombosis didn’t
depend on the site nor on the technic of implantation. There was no correlation
between this complication and stent sizes despite that it seems to be more fre-
quent in the case of longer stents (T+=24,32 ;T- = 22,13 ; p=0,47) and in the
case of small diameter (T+= 2,82 ;T-=2,94 ; p=0,36). Predictive factors of
stent thrombosis were clopidogrel withdrawal for surgery (T+=43,47% ; T-
=27,51 %; p=0,09), the early withdrawal of clopidogrel (T+=13,99 mois ; T-=
9,08mois ;p=0,02). Stent thrombosis was associated to the increase of major
cardiovascular events (T+=39,13% ;T =9,7% ;p<0,001) especially myocardial
infarction (T+= 21,7% ;T-= 1,67 ; p<0,001), the rate of revascularisa-
tion(T+=13,04 ; T-=3,35% ;p=0,01) but there was no significant effect on the
mortality (T+= 8,6% ;T-= 3,02% ;p=0,13).
Instent thrombosis is a lifethreatening complication occurring in 0 to 3,5%
based on randomized studies. It is more frequent in case of drug eluting stenting.
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Aim: To describe the characteristics and results of Percutaneous coronary
intervention (PCI) for unprotected left main coronary artery (ULMCA) disease
in octogenarians and to outline the predictors of outcomes
Methods: 80 consecutive patients≥80 years that underwent ULMCA
angioplasty in our institution between 2004 and 2008 were included. The Cox
regression model was used to analyse long term predictors of Major adverse
cardiac events (cardiac death, non fatal Q wave MI, or TLR). 
Results: Mean age was 84 ±3.4 years. 49 (61.3%) were men, 19 (23.8%) had
diabetes mellitus.11 (13.8%) patients presented with STEMI, 43 (54%) with
NSTEMI/UA, 9 (11.3%) with stable angina, 14 (17.5%) with silent ischemia and
1 (1.3%) with syncope. Mean additive EuroSCORE value was 10.8±3.8 and
mean predicted surgical mortality by logistic EuroSCORE was 26.7%. 28
patients (54.9%) had 3-vessel disease. Distal Left main lesions were found in 46
cases (57.5%). the provisional side-branch T-stenting approach with kissing bal-
loon inflation was used in 92.3% of cases. Drug eluting stents were used in only
14 patients (27%). Angiographic success was obtained in all cases. 
After a mean follow up of 30.42 months, 8 (10%) cardiac deaths were
recorded, 8 (10%) patients had TLR, combined MACE occurred in 17 patients
(21.3%).
By univariate analysis, only left ventricular ejection fraction<50%
(p=0.025; HR=5.08, 95% CI [1.1-15.4]) and EuroSCORE values>10 (p=0.004;
HR=8.09, 95% CI [3.3-35.4]) were associated with a higher incidence of long
term cardiac death, but on multivariate analysis, EuroSCORE was the only
independent predictor of cardiac death (p=0.01; HR=8.4, 95% CI [4.1-28.4]).
Similarly, higher EuroSCORE values constituted the only variable associated
with MACE (p=0.034; HR=3.2, 95% CI [1.1-9.4]).
Conclusion: ULMCA stenting in octogenarians proved to be a feasible and
safe procedure associated with acceptable short and long term outcomes. Euro-
SCORE was the only predictor of both cardiac death and MACE. 
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Objectives: We sought to assess the efficacy and safety of the PES used in
everyday practice in diabetic patients (DP) with single or multiple vessel disease
compared to non-diabetic patients (NDP) over at least 3 years. Safety concerns
about PES have been raised, particularly when used in less highly selected
patients than those included in randomized trials and especially among DP. 
Methods: The EVASTENT-Tax study is a multicenter matched cohort reg-
istry of 502 patients (pts) revascularised exclusively with paclitaxel stents
(Taxus®). For each DP included a NDP patient was subsequently included.
